Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ.

Autor: Porrett PM; Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania., Reese PP; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Holzmayer V; Abbott Laboratories, Abbott Park, Illinois., Coller KE; Abbott Laboratories, Abbott Park, Illinois., Kuhns M; Abbott Laboratories, Abbott Park, Illinois., Van Deerlin VM; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Gentile C; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Smith JR; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Sicilia A; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Woodards A; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., McLean R; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Abt P; Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania., Bloom RD; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Reddy KR; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Blumberg E; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Cloherty G; Abbott Laboratories, Abbott Park, Illinois., Goldberg D; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Jazyk: angličtina
Zdroj: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2019 Sep; Vol. 19 (9), pp. 2525-2532. Date of Electronic Publication: 2019 May 28.
DOI: 10.1111/ajt.15415
Abstrakt: Hepatitis C virus (HCV) seroconversion among HCV-uninfected transplant recipients from HCV-infected (NAT+/Antibody+) or HCV-exposed (NAT-/Antibody+) donors has been reported. However, the origin of anti-HCV antibody and the implications of seroconversion remain unknown. We longitudinally tested plasma from HCV-uninfected kidney (n = 31) or heart transplant recipients (n = 9) of an HCV NAT+ organ for anti-HCV antibody (both IgG and IgM isotypes). Almost half of all participants had detectable anti-HCV antibody at any point during follow-up. The majority of antibody-positive individuals became positive within 1-3 days of transplantation, and 6 recipients had detectable antibody on the first day posttransplant. Notably, all anti-HCV antibody was IgG, even in samples collected posttransplant day 1. Late seroconversion was uncommon (≈20%-25% of antibody+ recipients). Early antibody persisted over 30 days in kidney recipients, whereas early antibody dropped below detection in 50% of heart recipients within 2 weeks after transplant. Anti-HCV antibody is common in HCV-uninfected recipients of an HCV NAT+ organ. The IgG isotype of this antibody and the kinetics of its appearance and durability suggest that anti-HCV antibody is donor derived and is likely produced by a cellular source. Our data suggest that transfer of donor humoral immunity to a recipient may be much more common than previously appreciated.
(© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.)
Databáze: MEDLINE
Externí odkaz: